Full Breakdown
FDA Approves First OTC Tylenol® with Naproxen Combination Amid Ongoing Texas Lawsuit
7/25/2026, 8:34:21 PM
Core Event – FDA Authorization of a Fixed-Dose Tylenol® with Naproxen
On July 24, 2026, the U.S. Food and Drug Administration (FDA) approved an over-the-counter tablet that combines 650 mg of acetaminophen (Tylenol®) with 220 mg of naproxen sodium. Marketed as “Tylenol® with Naproxen,” it is indicated for temporary relief of headaches, back pain, muscle aches, toothache, menstrual cramps, and minor arthritis pain in adults and children 12 years and older. The FDA granted Kenvue a three-year exclusivity period for this formulation.
Background & Context
Acetaminophen and naproxen sodium have been sold separately as OTC analgesics, but not together in a single dose. Kenvue cited a March 2026 consumer survey of 6,240 respondents showing that about 75 % of people with persistent pain were dissatisfied with existing OTC choices. The company presented the new product as a non-opioid option that could simplify dosing and reduce reliance on prescription opioids.
Data & Statistics
- Fixed-dose composition: 650 mg acetaminophen + 220 mg naproxen sodium.
- Clinical evidence: eight FDA-reviewed studies demonstrated superior pain relief compared with each ingredient alone.
- Onset of analgesia: under 30 minutes; duration of effect: up to 12 hours per dose.
- Consumer dissatisfaction: roughly 75 % of persistent-pain sufferers (Kenvue Pain Consumer Survey, March 2026).
Official Statements & Responses
The FDA release linked the approval to the administration’s healthcare agenda. Kenvue’s chief medical officer, Dr. Rajesh Mishra, said the milestone “reflects the long-standing leadership of Tylenol® in translating rigorous clinical science into accessible, over-the-counter solutions.” He added that the combination “simplifies” pain management with fast onset, 12-hour duration, and a safety profile based on two well-established non-opioid ingredients.
Michelle Bateson, head of North America R&D at Kenvue, explained that acetaminophen “quickly reduces pain signals” while naproxen “targets pain associated with inflammation,” supporting the multimodal approach. The FDA noted nationwide distribution through major retailers, and Kenvue plans to present detailed clinical data at PAINWeek 2026.
Conflicting Reports & Gaps
- Safety in pregnancy: President Trump’s 2025 statements warned of a link between acetaminophen and autism, while doctors and professional societies maintain that acetaminophen remains safe for pregnant patients. The FDA’s approval documents do not address this controversy.
- Long-term outcomes: The eight clinical studies focus on short-term analgesic efficacy; data on chronic use, especially in pregnant populations, were not disclosed.
What’s Next
Kenvue expects Tylenol® with Naproxen to reach major U.S. retailers “soon.” The company will share additional clinical findings at upcoming medical congresses, including PAINWeek 2026. Regulatory filings, including Kenvue’s annual report for the fiscal year ended December 28, 2025, contain forward-looking statements about the product’s market rollout and potential risks.
